3 Stocks Underperforming Today In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.5%) at 16,894 as of Thursday, July 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 864 issues advancing vs. 2,123 declining with 163 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Sanofi ( SNY), down 1.2%, Valeant Pharmaceuticals International ( VRX), down 1.0%, Novartis ( NVS), down 0.8%, Allergan ( AGN), down 0.6% and Amgen ( AMGN), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.64 (-0.8%) to $74.40 on light volume. Thus far, 585,730 shares of AstraZeneca exchanged hands as compared to its average daily volume of 5.7 million shares. The stock has ranged in price between $74.08-$74.66 after having opened the day at $74.13 as compared to the previous trading day's close of $75.04.

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. AstraZeneca has a market cap of $94.3 billion and is part of the health care sector. Shares are up 26.4% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst that rates AstraZeneca a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Actavis ( ACT) is down $1.62 (-0.8%) to $215.66 on light volume. Thus far, 765,703 shares of Actavis exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $213.28-$216.44 after having opened the day at $213.47 as compared to the previous trading day's close of $217.28.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $37.8 billion and is part of the health care sector. Shares are up 29.3% year-to-date as of the close of trading on Wednesday. Currently there are 15 analysts that rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.15 (-0.5%) to $29.90 on average volume. Thus far, 11.7 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.0 million shares. The stock has ranged in price between $29.58-$29.92 after having opened the day at $29.82 as compared to the previous trading day's close of $30.05.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $192.3 billion and is part of the health care sector. Shares are down 1.9% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Stocks Trade Lower as Rates Continue Rising; Boeing Holds Gains

Stocks Trade Lower as Rates Continue Rising; Boeing Holds Gains

4 Stocks Making Important Moves Wednesday

4 Stocks Making Important Moves Wednesday

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday